The Evolution: From Single to Triple
GLP-1 agonists have evolved through three generations:
- First generation (single agonist): Semaglutide (Ozempic/Wegovy), liraglutide (Victoza/Saxenda) — target GLP-1 receptor only. 15–17% weight loss.
- Second generation (dual agonist): Tirzepatide (Mounjaro/Zepbound) — targets GLP-1 + GIP receptors. 20–22% weight loss.
- Third generation (triple agonist): Retatrutide — targets GLP-1 + GIP + glucagon receptors. Up to 28.7% weight loss.
Each generation builds on the last, adding receptor targets for compounding metabolic effects.
The Big Four: 2026's Most Important Candidates
1. Retatrutide (Eli Lilly) — Triple Agonist 💊
Mechanism: Simultaneously activates GLP-1, GIP, and glucagon receptors — the first triple agonist to reach Phase 3.
Weight loss: 28.7% (12 mg dose) in TRIUMPH-4 — the highest weight loss ever recorded in a controlled trial for any obesity drug.
Diabetes: A1C reductions of 2.0%+ with significant improvements in insulin sensitivity.
Beyond weight: Phase 3 trials are exploring MASH/NASH (liver disease), sleep apnea, cardiovascular outcomes, and osteoarthritis.
Timeline: Seven Phase 3 trials running in 2025–2026. FDA submission expected late 2026 or early 2027.
Side effects: Higher GI adverse events at top doses. New class effect: dysesthesia (tingling/numbness) reported in some patients. May require careful dose titration.
2. Orforglipron (Eli Lilly) — First Oral GLP-1 Pill 💊
Mechanism: A non-peptide, small-molecule oral GLP-1 agonist. Unlike oral semaglutide (Rybelsus), it does not require fasting before dosing — a major convenience advantage.
Weight loss: 12.4% mean weight loss at 72 weeks (ATTAIN-1 trial) — modest vs. injectables but with the massive advantage of being a daily pill.
FDA Status: Approved April 2026 as Foundayo™ — the first oral GLP-1 for obesity with no food or water restrictions.
Why it matters: Many patients refuse injectable medications. Orforglipron makes GLP-1 therapy accessible to the needle-averse majority. It's also cheaper to manufacture than peptide-based drugs.
Limitations: Lower efficacy than injectable counterparts. Not yet approved for type 2 diabetes (trials ongoing).
3. CagriSema (Novo Nordisk) — Amylin + GLP-1 Combo 💊
Mechanism: Combines cagrilintide (an amylin analogue) with semaglutide in a single weekly injection. Amylin complements GLP-1 by targeting different satiety pathways in the brain.
Weight loss: ~23% in REDEFINE 1 (Phase 3) — significantly better than semaglutide alone (16.6%).
FDA filing: Submitted December 2025. Decision expected H2 2026.
The Novo play: As Ozempic faces generic competition globally, CagriSema is Novo Nordisk's next-generation flagship — protected by new patents through the 2030s.
4. Survodutide (Boehringer Ingelheim) — GLP-1 + Glucagon 💊
Mechanism: Dual agonist targeting GLP-1 and glucagon receptors. The glucagon component specifically drives liver fat reduction.
Weight loss: ~18.7% in Phase 2 — strong, though below retatrutide.
Unique angle: Leading candidate for MASH/NASH (fatty liver disease) — a $35 billion unmet market with no approved drug therapies until recently.
Timeline: Late-stage Phase 3. FDA decision expected 2026–2027.
Head-to-Head Comparison
| Drug | Type | Route | Max Weight Loss | Status |
|---|---|---|---|---|
| Semaglutide (Wegovy) | Single (GLP-1) | Weekly injection | ~16.9% | ✅ Approved |
| Tirzepatide (Zepbound) | Dual (GLP-1/GIP) | Weekly injection | ~22.5% | ✅ Approved |
| Orforglipron (Foundayo) | Single (GLP-1) | Daily pill | ~12.4% | ✅ Approved Apr 2026 |
| CagriSema | Dual (GLP-1/Amylin) | Weekly injection | ~23% | 📋 FDA filing |
| Survodutide | Dual (GLP-1/Glucagon) | Weekly injection | ~18.7% | 🔬 Phase 3 |
| Retatrutide | Triple (GLP-1/GIP/Glucagon) | Weekly injection | ~28.7% | 🔬 Phase 3 |
| Amycretin | Single peptide (GLP-1/Amylin) | Weekly injection | ~25%* | 🔬 Phase 3 |
*Phase 2 data — Phase 3 results pending
The Bigger Picture: Beyond Diabetes and Obesity
What's remarkable about the GLP-1 class is how many conditions they're showing benefit in:
- Cardiovascular disease: Semaglutide reduced major adverse cardiovascular events by 20% (SELECT trial)
- Liver disease (MASH): Survodutide and semaglutide both showing liver fat reversal in trials
- Chronic kidney disease: FLOW trial showed semaglutide reduced kidney disease progression by 24%
- Sleep apnea: Tirzepatide reduced apnea-hypopnea index by 50%+ in SURMOUNT-OSA
- Addiction: Early evidence suggests GLP-1 agonists may reduce alcohol and nicotine cravings
- Heart failure: STEP-HFpEF showed semaglutide improved symptoms and quality of life
Bottom line: We're witnessing the emergence of a "metabolic reset" drug class. The question isn't whether these drugs work — it's which combination, dose, and delivery route is right for each patient. And as semaglutide patents expire, access will improve dramatically in most of the world.
What Patients Should Know
- Don't wait for "the best" drug. Semaglutide and tirzepatide are available now and highly effective. Perfect is the enemy of good.
- Oral options are here. If you've been avoiding GLP-1s because of needles, Orforglipron (Foundayo) is FDA-approved as of April 2026.
- Side effects are real. GI symptoms (nausea, constipation, diarrhea) affect 30–50% of patients, especially during dose titration. Most improve over 4–8 weeks.
- Weight regain is the challenge. Stopping GLP-1s leads to weight regain in most patients. These are likely lifelong medications for many.
- Cost varies wildly. From ₹2,000/month (generic semaglutide in India) to $1,300/month (branded in the US). Compare costs globally.
Track Your Diabetes Journey
Monitor A1C, weight, medications, and more — with AI-powered insights.
Start Free →